PHOTOCURE ASA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.2 NOK | -0.37% |
|
-1.09% | -19.58% |
| Sales 2023 | 446M 40.63M | Sales 2024 * | 495M 45.07M | Capitalization | 1.47B 134M |
|---|---|---|---|---|---|
| Net income 2023 | - 0 | Net income 2024 * | - 0 | EV / Sales 2023 | 4.09 x |
| Net cash position 2023 * | 238M 21.72M | Net cash position 2024 * | 256M 23.31M | EV / Sales 2024 * | 2.46 x |
| P/E ratio 2023 |
6,740
x | P/E ratio 2024 * |
1,282
x | Employees | 88 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 98.3% |
More Fundamentals
* Assessed data
More news
Latest transcript on Photocure ASA
More press releases
| 1 day | -0.37% | ||
| 1 week | -1.09% | ||
| Current month | -1.45% | ||
| 1 month | -3.90% | ||
| 3 months | -21.45% | ||
| 6 months | +3.63% | ||
| Current year | -19.58% |
1 week
52.70
55.50
1 month
52.7059.30
Current year
52.0071.90
1 year
40.7071.90
3 years
40.70154.50
5 years
40.00154.50
10 years
17.70154.50
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Schneider
CEO | Chief Executive Officer | - | 18-10-31 |
Erik Dahl
DFI | Director of Finance/CFO | - | 12-08-14 |
Anders Neijber
CTO | Chief Tech/Sci/R&D Officer | - | 21-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Johanna Holldack
BRD | Director/Board Member | - | 17-04-27 |
Malene Brondberg
BRD | Director/Board Member | 51 | - |
Dylan Hallerberg
CHM | Chairman | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 54.2 | -0.37% | 6 302 |
| 24-04-22 | 54.4 | -0.73% | 25,552 |
| 24-04-19 | 54.8 | +1.67% | 39,437 |
| 24-04-18 | 53.9 | +0.19% | 18,198 |
| 24-04-17 | 53.8 | -1.82% | 46,834 |
Real-time Oslo Bors, April 23, 2024 at 04:37 am EDT
More quotes
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Companyâs activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Sector
Pharmaceuticals
Calendar
2024-05-14
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
54.4
NOK
Average target price
86
NOK
Spread / Average Target
+58.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.58% | 134M | |
| +25.46% | 659B | |
| +25.83% | 557B | |
| -4.86% | 359B | |
| +16.44% | 322B | |
| +8.34% | 297B | |
| +6.09% | 215B | |
| +8.08% | 210B | |
| -6.22% | 200B | |
| -8.79% | 149B |
- Stock Market
- Equities
- PHO Stock
